Document is current
Any future updates will be listed below
-
Authors
Liu, Annie
Lowe, Melissa
Niedzwiecki, Donna
Rhodin, Kristen E.
Sharib, Jeremy
Wildman-Tobriner, Benjamin
Wong, Terence Z.
Kim, Charles Y.
Thacker, Julie
Mantyh, Christopher
Migaly, John
Lan, Billy Y.
Strickler, John H.
David Hsu, S.
Nussbaum, Daniel
Zani, Sabino
Uronis, Hope
Allen, Peter J.
Lidsky, Michael E.
- License Information
-
More Information
Article History
Received: 10 June 2024
Accepted: 29 October 2024
First Online: 20 November 2024
Disclosures
: John H. Strickler reports consultant or advisory roles for Abbvie, Agenus, Astellas, AstraZeneca, Bayer, Beigene, Daiichi-Sankyo, Eli Lilly, GSK, Johnson and Johnson, Jazz Pharmaceuticals, Merck, Natera, Pfizer, Roche/Genentech, Regeneron, Sanofi, Taiho, Takeda, and Xilio Therapeutics; stock options for Triumvira Immunologics; and research funding or contracted research for Abbvie, Amgen, AStar D3, Bayer, Beigene, Curegenix, Daiichi-Sankyo, Eli Lilly, Erasca, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, and Roche/Genentech. Benjamin Wildman-Tobriner reports a consultant role for See-Mode Technologies. Annie Liu, Melissa Lowe, Donna Niedzwiecki, Kristen E. Rhodin, Jeremy Sharib, Terence Z. Wong, Charles Y. Kim, Julie Thacker, Christopher Mantyh, John Migaly, Billy Y. Lan, S. David Hsu, Daniel Nussbaum, Sabino Zani, Hope Uronis, Peter J. Allen, and Michael E. Lidsky have no disclosures to declare that may be relevant to the contents of this study.
